Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as SHPL-49 Injection
SHPL-49 · 1 trial · 1 indication
Proportion of participants with mRS scores of 0-1 at Day 90
| Arm | Type | Description |
|---|---|---|
| SHPL-49 Injection | EXPERIMENTAL | 3mL/ ampoule |
| Placebo Injection | PLACEBO_COMPARATOR | 3mL/ ampoule |
| Name | Type | Description |
|---|---|---|
| SHPL-49 Injection | DRUG | 2 ampoules of SHPL-49 Injection in 100 mL 0.9% sodium chloride will be administered as a 30-minute intravenous infusion and applied twice daily for 7 days. |
| Placebo Injection | DRUG | 2 ampoules of Placebo Injection in 100 mL 0.9% sodium chloride will be administered as a 30-minute intravenous infusion and applied twice daily for 7days. |
Inclusion Criteria: 1. Age 18-80 years old (including upper and lower limits); 2. Clinically diagnosed as acute ischemic stroke according to the latest guidelines; 3. Patients diagnosed as acute ischemic stroke who plan to receive or have received standard intravenous thrombolysis in hospital (this...
SHPL-49 is an investigational small molecule being developed for the treatment of acute ischemic stroke. It is currently in Phase 3 clinical development and is not yet approved by regulatory authorities.
SHPL-49 is being developed by HUTCHMED (China) Limited, a biopharmaceutical company listed on the stock exchange under the ticker HCM.
SHPL-49 is currently in Phase 3 clinical development. It is an investigational drug and has not been approved for any use.
SHPL-49 is being evaluated in a Phase 3 clinical trial with the identifier NCT07241520. This randomized, double-blind, placebo-controlled study is recruiting 1,096 participants with acute ischemic stroke in China.
Yes, SHPL-49 is also known as SHPL-49 Injection. Both names refer to the same investigational drug being developed for acute ischemic stroke.